SLYND Drug Patent Profile
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
When do Slynd patents expire, and when can generic versions of Slynd launch?
Slynd is a drug marketed by Exeltis Usa Inc and is included in one NDA. There are thirteen patents protecting this drug and one Paragraph IV challenge.
This drug has sixty-one patent family members in twenty-eight countries.
The generic ingredient in SLYND is drospirenone. There are eleven drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the drospirenone profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Slynd
A generic version of SLYND was approved as drospirenone by EXELTIS USA INC on June 29th, 2022.
Summary for SLYND
| International Patents: | 61 |
| US Patents: | 13 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 79 |
| Patent Applications: | 2,536 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for SLYND |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for SLYND |
| What excipients (inactive ingredients) are in SLYND? | SLYND excipients list |
| DailyMed Link: | SLYND at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for SLYND
Generic Entry Date for SLYND*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Anatomical Therapeutic Chemical (ATC) Classes for SLYND
Paragraph IV (Patent) Challenges for SLYND
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| SLYND | Tablets | drospirenone | 4 mg | 211367 | 1 | 2022-01-07 |
US Patents and Regulatory Information for SLYND
SLYND is protected by thirteen US patents and one FDA Regulatory Exclusivity.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of SLYND is ⤷ Try a Trial.
This potential generic entry date is based on patent ⤷ Try a Trial.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting SLYND
Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: PREVENTION OF PREGNANCY IN FEMALES OF REPRODUCTIVE AGE
Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: PREVENTION OF PREGNANCY IN FEMALES OF REPRODUCTIVE AGE
Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: PREVENTION OF PREGNANCY IN FEMALES OF REPRODUCTIVE AGE
Synthetic progestogens and pharmaceutical compositions comprising the same
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Synthetic progestogens and pharmaceutical compositions comprising the same
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Synthetic progestogens and pharmaceutical compositions comprising the same
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Synthetic progestogens and pharmaceutical compositions comprising the same
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Synthetic progestogens and pharmaceutical compositions comprising the same
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Synthetic progestogens and pharmaceutical compositions comprising the same
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: PREVENTION OF PREGNANCY IN FEMALES OF REPRODUCTIVE AGE
Synthetic progestogens and pharmaceutical compositions comprising the same
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Patented Use: PREVENTION OF PREGNANCY IN FEMALES OF REPRODUCTIVE AGE
FDA Regulatory Exclusivity protecting SLYND
NEW PRODUCT
Exclusivity Expiration: ⤷ Try a Trial
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Exeltis Usa Inc | SLYND | drospirenone | TABLET;ORAL | 211367-001 | May 23, 2019 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Exeltis Usa Inc | SLYND | drospirenone | TABLET;ORAL | 211367-001 | May 23, 2019 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| Exeltis Usa Inc | SLYND | drospirenone | TABLET;ORAL | 211367-001 | May 23, 2019 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Exeltis Usa Inc | SLYND | drospirenone | TABLET;ORAL | 211367-001 | May 23, 2019 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for SLYND
When does loss-of-exclusivity occur for SLYND?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Argentina
Patent: 1670
Estimated Expiration: ⤷ Try a Trial
Australia
Patent: 11273605
Estimated Expiration: ⤷ Try a Trial
Brazil
Patent: 2012033391
Estimated Expiration: ⤷ Try a Trial
Patent: 2019008317
Estimated Expiration: ⤷ Try a Trial
Canada
Patent: 03721
Estimated Expiration: ⤷ Try a Trial
Patent: 03062
Estimated Expiration: ⤷ Try a Trial
Patent: 61421
Estimated Expiration: ⤷ Try a Trial
Chile
Patent: 12003685
Estimated Expiration: ⤷ Try a Trial
Colombia
Patent: 40328
Estimated Expiration: ⤷ Try a Trial
Croatia
Patent: 0200155
Estimated Expiration: ⤷ Try a Trial
Patent: 0220332
Estimated Expiration: ⤷ Try a Trial
Cyprus
Patent: 22544
Estimated Expiration: ⤷ Try a Trial
Denmark
Patent: 88114
Estimated Expiration: ⤷ Try a Trial
Patent: 32448
Estimated Expiration: ⤷ Try a Trial
Ecuador
Patent: 12012359
Estimated Expiration: ⤷ Try a Trial
Patent: 15032906
Estimated Expiration: ⤷ Try a Trial
Patent: 15032911
Estimated Expiration: ⤷ Try a Trial
Eurasian Patent Organization
Patent: 8680
Estimated Expiration: ⤷ Try a Trial
Patent: 1291372
Estimated Expiration: ⤷ Try a Trial
European Patent Office
Patent: 88114
Estimated Expiration: ⤷ Try a Trial
Patent: 32448
Estimated Expiration: ⤷ Try a Trial
Patent: 56186
Estimated Expiration: ⤷ Try a Trial
Guatemala
Patent: 1200336
Estimated Expiration: ⤷ Try a Trial
Patent: 1200336A
Estimated Expiration: ⤷ Try a Trial
Patent: 1200336B
Estimated Expiration: ⤷ Try a Trial
Hungary
Patent: 47689
Estimated Expiration: ⤷ Try a Trial
Patent: 58176
Estimated Expiration: ⤷ Try a Trial
Patent: 000016
Estimated Expiration: ⤷ Try a Trial
Patent: 200018
Estimated Expiration: ⤷ Try a Trial
Japan
Patent: 10159
Estimated Expiration: ⤷ Try a Trial
Patent: 13529665
Estimated Expiration: ⤷ Try a Trial
Lithuania
Patent: 2021523
Estimated Expiration: ⤷ Try a Trial
Patent: 2022513
Estimated Expiration: ⤷ Try a Trial
Patent: 88114
Estimated Expiration: ⤷ Try a Trial
Patent: 32448
Estimated Expiration: ⤷ Try a Trial
Mexico
Patent: 9952
Estimated Expiration: ⤷ Try a Trial
Patent: 4971
Estimated Expiration: ⤷ Try a Trial
Patent: 12014629
Estimated Expiration: ⤷ Try a Trial
Patent: 19004393
Estimated Expiration: ⤷ Try a Trial
New Zealand
Patent: 5176
Estimated Expiration: ⤷ Try a Trial
Norway
Patent: 20015
Estimated Expiration: ⤷ Try a Trial
Peru
Patent: 130780
Estimated Expiration: ⤷ Try a Trial
Patent: 161410
Estimated Expiration: ⤷ Try a Trial
Poland
Patent: 88114
Estimated Expiration: ⤷ Try a Trial
Patent: 32448
Estimated Expiration: ⤷ Try a Trial
Portugal
Patent: 88114
Estimated Expiration: ⤷ Try a Trial
Patent: 32448
Estimated Expiration: ⤷ Try a Trial
Serbia
Patent: 826
Estimated Expiration: ⤷ Try a Trial
Patent: 027
Estimated Expiration: ⤷ Try a Trial
Slovenia
Patent: 88114
Estimated Expiration: ⤷ Try a Trial
Patent: 32448
Estimated Expiration: ⤷ Try a Trial
South Africa
Patent: 1209743
Estimated Expiration: ⤷ Try a Trial
South Korea
Patent: 2164693
Estimated Expiration: ⤷ Try a Trial
Patent: 2210982
Estimated Expiration: ⤷ Try a Trial
Patent: 130048227
Estimated Expiration: ⤷ Try a Trial
Patent: 170085604
Estimated Expiration: ⤷ Try a Trial
Patent: 190073598
Estimated Expiration: ⤷ Try a Trial
Patent: 210013663
Estimated Expiration: ⤷ Try a Trial
Spain
Patent: 77886
Estimated Expiration: ⤷ Try a Trial
Patent: 08657
Estimated Expiration: ⤷ Try a Trial
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering SLYND around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Spain | 2777886 | ⤷ Try a Trial | |
| Croatia | P20200155 | ⤷ Try a Trial | |
| Japan | 2013529665 | ⤷ Try a Trial | |
| Canada | 3003062 | COMPOSITION PHARMACEUTIQUE CONTENANT DE LA DROSPIRENONE ET KIT CONTRACEPTIF (PHARMACEUTICAL COMPOSITION COMPRISING DROSPIRENONE AND CONTRACEPTIVE KIT) | ⤷ Try a Trial |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for SLYND
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2588114 | LUC00227 | Luxembourg | ⤷ Try a Trial | PRODUCT NAME: DROSPIRENONE; AUTHORISATION NUMBER AND DATE: 31332 20191022 |
| 2588114 | 122021000065 | Germany | ⤷ Try a Trial | PRODUCT NAME: DROSPIRENON; NAT. REGISTRATION NO/DATE: 7002248.00.00 20210426; FIRST REGISTRATION: DK 61678 20191016 |
| 3632448 | 2022C/529 | Belgium | ⤷ Try a Trial | PRODUCT NAME: DROSPIRENON; AUTHORISATION NUMBER AND DATE: BE548284 20191107 |
| 1380301 | 2009C/007 | Belgium | ⤷ Try a Trial | PRODUCT NAME: DROSPIRENONE-ETHINYLESTRADIOL; AUTHORISATION NUMBER AND DATE: BE321386 20080811 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2023 - 2024
NCE-1 Patent Challenge Dates 2023 - 2024
DrugChatter - AI-based answers to questions about drugs
RxJam - Trigger-based marketing for life sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2023, www.DrugPatentWatch.com.
Follow DrugPatentWatch:
